Xilio Therapeutics (XLO) Cash from Financing Activities (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Cash from Financing Activities data on file, last reported at $35.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 638.97% year-over-year to $35.7 million; the trailing twelve-month figure through Mar 2026 stood at $118.6 million (up 258.74% YoY), and the FY2025 full-year result was $87.8 million, up 200.64% from the prior year.
• Cash from Financing Activities steadied at $35.7 million in Q1 2026, from $35.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $47.4 million in Q2 2025 to a low of -$2.2 million in Q3 2023.
• A 5-year average of $8.6 million and a median of -$5000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 33660.0% in 2023 and jumped 2120.46% in 2024, its largest moves.
• Tracing XLO's Cash from Financing Activities over 5 years: stood at -$21000.0 in 2022, then tumbled by 7680.95% to -$1.6 million in 2023, then soared by 601.96% to $8.2 million in 2024, then surged by 337.28% to $35.9 million in 2025, then retreated by 0.44% to $35.7 million in 2026.
• Business Quant data shows XLO's Cash from Financing Activities at $35.7 million in Q1 2026, $35.9 million in Q4 2025, and -$285000.0 in Q3 2025.